Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
15.47
-0.03 (-0.19%)
May 15, 2025, 4:00 PM - Market closed
Tourmaline Bio Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Tourmaline Bio stock ranges from a low of $25 to a high of $70. The average analyst price target of $49.33 forecasts a 218.88% increase in the stock price over the next year.
Price Target: $49.33 (+218.88%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tourmaline Bio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 2 | 2 | 3 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $50 | Strong Buy | Reiterates | $50 | +223.21% | May 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $70 | Strong Buy | Maintains | $70 | +352.49% | May 5, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +352.49% | Apr 23, 2025 |
| Wedbush | Wedbush | Buy Maintains $42 → $43 | Buy | Maintains | $42 → $43 | +177.96% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $50 | Strong Buy | Maintains | $49 → $50 | +223.21% | Mar 14, 2025 |
Financial Forecast
Revenue This Year
112.87M
from 23.14M
Increased by 387.73%
Revenue Next Year
n/a
from 112.87M
EPS This Year
-3.55
from -2.89
EPS Next Year
-4.23
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.0M | 63.0M | 63.0M | ||
| Avg | 6.8M | 7.7M | 14.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 172.2% | 826.5% | 723.5% | ||
| Avg | -70.6% | 12.5% | 84.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.89 | -2.98 | -2.99 | ||
| Avg | -3.55 | -4.23 | -5.16 | ||
| Low | -4.56 | -5.85 | -9.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.